KatopodisK.P., AndrikosE.K., GouvaC.D., BairaktariE.T., NikolopoulosP.M., TakouliL.K.Sevelamer hydrochloride versus aluminum hydroxide: effect on serum phosphorus and lipids in CAPD patients.Perit Dial Int2006; 26: 320–7.
2.
National Kidney Foundation.K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease.Am J Kidney Dis2003; 42(Suppl 3): S1–202.
3.
SheikhM.S., MaguireJ.A., EmmettM., Santa AnaC.A., NicarM.J., SchillerL.R.Reduction of dietary phosphorus absorption by phosphorus binders. A theoretical, in vivo in vitro study.J Clin Invest1989; 83: 66–73.
4.
JanssenM.J., van der KuyA., ter WeeP.M., van BovenW.P.Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients.Clin Nephrol1996; 45: 111–19.
5.
LauA.H., KukJ.M., FransonK.L.Phosphate-binding capacities of calcium and aluminum formulations.Int J Artif Organs1998; 21: 19–22.
6.
EmmettM.A comparison of clinically useful phosphorus binders for patients with chronic kidney failure.Kidney Int Suppl2004; 90: S25–32.
7.
Al-BaajF., SpeakeM., HutchisonA.J.Control of serum phosphate by oral lanthanum carbonate in patients undergoing haemodialysis and continuous ambulatory peritoneal dialysis in a short-term, placebo-controlled study.Nephrol Dial Transplant2005; 20: 775–82.
8.
CanaveseC., MereuC., NordioM., SabbioniE., AimeS.Blast from the past: the aluminum's ghost on the lanthanum salts.Curr Med Chem2005; 12: 1631–6.
9.
BehetsG.J., VerberckmoesS.C., D'HaeseP.C., De BroeM.E.Lanthanum carbonate: a new phosphate binder.Curr Opin Nephrol Hypertens2004; 13: 403–9.
10.
ChertowG.M., BurkeS.K., RaggioP., Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients.Kidney Int2002; 62: 245–52.
11.
QunibiW.Y., HootkinsR.E., MacDowellL.L., MyerM.S., SimonM., GarzaR.O.Treatment of hyperphosphatemia in hemodialysis patients: the Calcium Acetate Renagel Evaluation (CARE Study).Kidney Int2004; 65: 1914–26.
12.
WinchesterJ.F., RotellarC., GogginsM., RobinoD., RakowskiT.A., ArgyW.P.Calcium and phosphate balance in dialysis patients.Kidney Int Suppl1993; 41: S174–8.
13.
MannsB., StevensL., MiskulinD., OwenW.F.Jr., WinkelmaterW.C., TonelliM.A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States.Kidney Int2004; 66: 1239–47.
14.
NoordzijM., KorevaarJ.C., BoeschotenE.W., DekkerF.W., BosW.J., KredietR.T.Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines for bone metabolism and disease in CKD: association with mortality in dialysis patients.Am J Kidney Dis2005; 46: 925–32.
15.
WangAY-M, WooJ., Man-MeiW., LawM-C, LuiS-F, LiPK-T.Hyperphosphatemia in Chinese peritoneal dialysis patients with and without residual kidney function: what are the implications?Am J Kidney Dis2004; 43: 712–20.
16.
DavenportA., GoelS., MacKenzieJ.C.Audit of the use of calcium carbonate as a phosphate binder in 100 patients treated with continuous ambulatory peritoneal dialysis.Nephrol Dial Transplant1992; 7: 632–5.
17.
SherrardD.J., HerczG., PeiY., MaloneyN.A., GreenwoodC., ManuelA.The spectrum of bone disease in end-stage renal failure—an evolving disorder.Kidney Int1993; 43: 436–42.
18.
SanchezC., Lopez-BareaF., Sanchez-CabezudoJ., BajoA., MateA., MartinezE.Low vs standard calcium dialysate in peritoneal dialysis: differences in treatment, biochemistry and bone histomorphometry. A randomized multicentre study.Nephrol Dial Transplant2004; 19: 1587–93.
19.
JonesM., HagenT., BoyleC.A., VoneshE., HamburgerR., CharytanC.Treatment of malnutrition with 1.1% amino acid peritoneal dialysis solution: results of a multicenter outpatient study.Am J Kidney Dis1998; 32: 761–9.
20.
le PooleC.Y., WeltenA.G., WeijmerM.C., ValentijnR.M., van IttersumF.J., ter WeeP.M.Initiating CAPD with a regimen low in glucose and glucose degradation products, with icodextrin and amino acids (NEPP) is safe and efficacious.Perit Dial Int2005; 25(Suppl 3): S64–8.
21.
TjiongH.L., van den BergJ.W., WattimenaJ.L., RietveldT., van DijkL.J., van der WeilA.M.Dialysate as food: combined amino acid and glucose dialysate improves protein anabolism in renal failure patients on automated peritoneal dialysis.J Am Soc Nephrol2005; 16: 1486–93.
22.
KoppleJ.D., Kalantar-ZadehK., MehrotraR.Risks of chronic metabolic acidosis in patients with chronic kidney disease.Kidney Int Suppl2005; 95: S21–7.
23.
BorrasM., MarcoM.P., FernandezE.Treatment with sevelamer decreases bicarbonate levels in peritoneal dialysis patients [Letter].Perit Dial Int2002; 22: 737.
24.
KasimatisE., MaksichD., JassalV., BargmanJ.M., OreopoulosD.G.Predictive factors of low HCO3- levels in peritoneal dialysis patients.Clin Nephrol2005; 63: 290–6.
25.
BrezinaB., QunibiW.Y., NolanC.R.Acid loading during treatment with sevelamer hydrochloride: mechanisms and clinical implications.Kidney Int Suppl2004; 90: S39–45.
PritchardS.S.Impact of dyslipidemia in end-stage renal disease.J Am Soc Nephrol2003; 14: S315–20.
28.
WannerC., KraneV., MarzW., OlschewskiM., MannJ.F., RufG.Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis [Published erratum appears in N Engl J Med 2005; 353: 1640].N Engl J Med2005; 353: 238–48.
29.
SigristM., BungayP., TaalM.W., McIntyreC.W.Vascular calcification and cardiovascular function in chronic kidney disease.Nephrol Dial Transplant2006; 21: 707–14.
30.
StompórT.P., PasowiczM., SulowiczS., Dembinska-KiecA., JandaK., WójcikK.Trends and dynamics of changes in calcification score over the 1 year observation period in patients on peritoneal dialysis.Am J Kidney Dis2004; 44: 517–28.
31.
MahdaviH., KuizonB.D., GalesB., WangH-J, ElashoffR.M., SaluskyI.B.Sevelamer hydrochloride: an effective phosphate binder in dialyzed children.Pediatr Nephrol2003; 18: 1260–4.
32.
QuerfeldU.The therapeutic potential of novel phosphate binders.Pediatr Nephrol2005; 20: 389–92.
33.
HuybrechtsK.F., CaroJ.J., WilsonD.A., O'BrienJ.A.Health and economic consequences of sevelamer use for hyperphosphatemia in patients on hemodialysis.Value Health2005; 8: 549–61.
